Syntara Ltd (ASX: SNT) Share Price and News

Mr Phillips has more than 30 years of operational management experience in the pharmaceutical and healthcare industry in Europe, Asia and Australia. From 1994 to 1998, he was Chief Executive Officer at Ciba Geigy in Hungary (Merged to form Novartis in 1996) where he led the launch of a portfolio of new products. After a period of three years as an Area Manager for Novartis responsible for 9 countries in Asia Pacific in 2001 he joined Novartis Australia as Group Company Head and Chief Executive Officer of its Pharmaceutical Division, launching leading oncology and ophthalmology products.

Dr Green is member of the Risk Committee. Dr Green is a global pharma executive with 30 years of experience in the biotechnology industry focused on the discovery, development and commercialisation of life saving medicines. Simon was actively involved in CSL's global expansion over a 17-year period and held roles as Senior Vice President, Global Plasma R&D and General Manager of CSL's manufacturing plants in Germany and Australia. Prior to joining CSL he worked in the USA at leading biotechnology companies Genentech Inc and Chiron Corporation. His skills cover R&D drug development, corporate due diligence, mergers and acquisitions, strategic planning, portfolio management, financial management, intellectual property management, business development, contract management and organisational design.

Dr Metters has over 25 years of experience in the discovery and development of therapies for treatment of diseases. She is currently working as an independent biopharma consultant and is a member of several boards including as a Non-Executive Director for Aslan Pharmaceuticals Ltd and an independent board member for HemoShear Therapeutics. From 2011-2014 Dr Metters was President and Chief Executive officer for Lycera Corp., a biopharmaceutical company establishing approaches to oral medicines for treatment of autoimmune diseases and cancer. He is also a member of the Risk Committee.

Mr Silva is a life sciences investment professional with knowledge of the biotech, pharmaceutical and medical technology sectors. Mr De Silva is currently the Founder and Managing Partner of KP Rx, an ANZ focused healthcare VC firm. KP Rx is seeded and supported by Karst Peak Capital where Mr De Silva was the Head of Healthcare Research until December 2022. His previous roles include associate healthcare analyst at Macquarie Group covering ASX-listed healthcare companies and lead healthcare analyst at CLSA Australia. Prior to moving into life science investment, he worked at Eli Lilly in various roles focused on the commercialisation of new and existing pharmaceuticals. He is also Chair of Risk Committee.

-

-

-

-

-

-